BriaCell Therapeutics Corp. financial data

Symbol
BCTX, BCTXW on Nasdaq
Location
3 Rd Floor, Bellevue Centre, 235 15 Th Str, West Vancouver, British Columbia, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
July 31
Former names
Ansell Capital Corp. (to 6/20/2014)
Latest financial report
10-K - Q2 2024 - Oct 29, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 205 % -92.3%
Return On Equity 130 % -99%
Return On Assets -44.7 % +28.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.2M shares +126%
Common Stock, Shares, Outstanding 18.3M shares +14.4%
Entity Public Float 63.7M USD -39.4%
Common Stock, Value, Issued 72.2M USD +3.7%
Weighted Average Number of Shares Outstanding, Basic 16.5M shares +5.35%
Weighted Average Number of Shares Outstanding, Diluted 16.5M shares +5.35%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 27.2M USD +77.2%
General and Administrative Expense 6.15M USD -22.5%
Operating Income (Loss) -33.3M USD -43.2%
Nonoperating Income (Expense) 263K USD -69.1%
Net Income (Loss) Attributable to Parent -4.79M USD +76.4%
Earnings Per Share, Basic -0.29 USD/shares +77.7%
Earnings Per Share, Diluted -0.29 USD/shares +77.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 862K USD -95.9%
Accounts Receivable, after Allowance for Credit Loss, Current 15.2K USD +2.26%
Assets, Current 3.65M USD -86.4%
Property, Plant and Equipment, Net 388K USD +15427%
Intangible Assets, Net (Excluding Goodwill) 200K USD -7.1%
Assets 5.87M USD -78.4%
Liabilities, Current 7.46M USD +314%
Accumulated Other Comprehensive Income (Loss), Net of Tax -139K USD 0%
Retained Earnings (Accumulated Deficit) -85.4M USD -5.94%
Stockholders' Equity Attributable to Parent -3.78M USD -137%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -2.68M USD +28.9%
Liabilities and Equity 5.87M USD -78.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.61M USD -115%
Net Cash Provided by (Used in) Financing Activities -47.3K USD
Common Stock, Shares, Issued 18.3M shares +14.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 862K USD -95.9%
Deferred Tax Assets, Valuation Allowance 18M USD +13.3%
Deferred Tax Assets, Gross 21.9M USD +37.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.9M USD +51.1%
Deferred Tax Assets, Operating Loss Carryforwards 5.55M USD +12.8%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 7.92M USD
Depreciation, Depletion and Amortization 3.82K USD +0.03%
Deferred Tax Assets, Net of Valuation Allowance 3.91M USD +8558%
Share-based Payment Arrangement, Expense 392K USD +39.5%